Emron Managed Care News 5-22-15

Combination Treatment for Cystic Fibrosis Shows Promise

Combining two medications that target the most common genetic cause of cystic fibrosis improved lung function in people with the disease. The combination therapy also reduced the rate of lung infections and other problems, according to a new study.

Prostate Cancer Testing Drops Off After Controversial Guidelines

Fewer American men are receiving prostate cancer screening in the wake of a national panel’s conclusion that the test does men more harm than good, a new study finds.

Study Suggests Dense Breast Tissue Isn’t Always a High Cancer Risk

A new study offers help to patients and doctors who are trying to deal with mammogram results that many women consider troubling and confusing: the finding of “dense” breast tissue.

Sarepta’s shares jump on initiation of FDA filing for DMD therapy eteplirsen

Shares in Sarepta Therapeutics climbed as much as 39 percent after the company announced that it reached an agreement with the FDA on the initiation of a rolling marketing application for eteplirsen for the treatment of Duchenne muscular dystrophy (DMD).

When Paying The Obamacare Penalty Is Cheaper Than Buying Insurance

When Angela Denig couldn’t cover the costs of Obamacare health insurance this year, she made the only decision she could: She gave up on coverage, paid the fee for not being insured and hoped she wouldn’t get sick.

Chemo before surgery benefits ovarian cancer patients

Women with advanced ovarian cancer who have chemotherapy before surgery suffered fewer side effects and tended to have a better quality of life than those following the traditional strategy of surgery first, a Cancer Research UK study has found.

Novartis drug Afinitor® extended progression-free survival in Phase III trial in advanced gastrointestinal or lung neuroendocrine tumors

Novartis announced today that the Phase III study of Afinitor® (everolimus) tablets plus best supportive care in patients with advanced nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin met its primary endpoint: significant extension of progression-free survival (PFS) compared to placebo plus best supportive care[1]. The RADIANT-4 study is part of one of the largest clinical trial programs in NET[1].

J&J plans to file 10 potential blockbusters by 2019

Johnson & Johnson says it plans to file 10 new molecular entities – each with the potential of pulling in sales in excess of $1 billion – and 40 line extensions of existing and new medicines by 2019.

CVS Health to buy pharmacy services provider Omnicare for $12.7 billion

Pharmacy benefit manager CVS Health announced Thursday an agreement to acquire pharmacy services provider Omnicare for $98.00 per share in cash, or a total enterprise value of approximately $12.7 billion. CVS noted that the deal will “significantly expand its ability to dispense prescriptions in assisted living and long-term care facilities, serving the senior patient population,” adding that the transaction will also expand its presence in the specialty pharmacy business.

Underinsured population doubled to 31M, report finds

There are now 31 million people who have health coverage with out-of-pocket costs or deductibles so high that they are considered “underinsured,” making them generally unable to take advantage of their health benefits, according to a newstudy from the Commonwealth Fund.

FDA approves Johnson & Johnson’s longer-acting schizophrenia therapy Invega Trinza

Johnson & Johnson’s Janssen Pharmaceuticals unit on Tuesday announced that the FDA approved Invega Trinza (paliperidone palmitate), a three-month long-acting atypical antipsychotic, for the treatment of schizophrenia. The company noted that the drug, which was cleared under the agency’s priority review programme, is “the first and only schizophrenia medication to be administered just four times a year, providing the longest dosing interval available.”

FDA Approves Invega Trinza

There’s a new treatment option for schizophrenia – Invega Trinza (three-month paliperidone palmitate), the first and only schizophrenia medication to be administered just four times a year, providing the longest dosing interval available.